Evidence map›Paper›PMID 31146483›Full record

ArticleMolecules (Basel, Switzerland)2019

Potent Anti-Ovarian Cancer with Inhibitor Activities on both Topoisomerase II and

Mohamed El-Naggar, Abd El-Galil E Amr, Ahmed A Fayed, Elsayed A Elsayed, Mohamed A Al-Omar, Mohamed M Abdalla

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Mohamed El-NaggarChemistry Department, Faculty of Sciences, University of Sharjah, Sharjah 27272, UAE. m5elnaggar@yahoo.com.
Abd El-Galil E AmrDrug Exploration & Development Chair (DEDC), Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. aamr@ksu.edu.sa.
Ahmed A FayedApplied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt. dr_ahmedfayed14@yahoo.com.
Elsayed A ElsayedZoology Department, Bioproducts Research Chair, College of Science, King Saud University, Riyadh 11451, Saudi Arabia. eaelsayed@ksu.edu.sa.
Mohamed A Al-OmarDrug Exploration & Development Chair (DEDC), Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. dr_ahmedfayed14@yahoo.com.
Mohamed M AbdallaAtos Pharma, Elkatyba Land, Belbis 44621, El Sharkya, Egypt. mmostafa201120@yahoo.com.
King Saud University · SATaibah University · SAUniversity of Sharjah · AE

Funding

King Saud University Vice Deanship of Scientific Research Chairs
6 · The paper itself

Abstract

A series of 16-(α-alkoxyalkane)-17-hydrazino-estra-1(10),2,4-trien[17,16-c]-3-ol (

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalChemistry Techniques, SyntheticDisease Models, AnimalEstroneFemaleHumansMiceProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTopoisomerase II InhibitorsXenograft Model Antitumor AssaysAntineoplastic AgentsEstroneProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTopoisomerase II Inhibitorsanti-ovarian cancerEstrone derivativeshydrazinekinase inhibitor.N-substituted pyrazolinetopoisomerase II inhibitor

Identifiers

PMID31146483
PMCPMC6600292
OpenAlexW2947913480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.